Clinical Trial

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-16.
Status change: Not Yet Recruiting → Recruiting 2024-08-22
Trial Details
NCT Number NCT06505395
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Gastrointestinal Neuroendocrine Pancreatic Tumor
Enrollment 90 participants
Start Date 2024-07-30
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-26